FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> lupus | Vitamin D

Researchers find two potential lupus vax treatments

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


After 5 decades without a new treatment, lupus patients got a reprieve in March with Human Genome Sciences' Benlysta. But doctors believe there are still better options down the pipeline for patients with the autoimmune disease. Two recent studies have brought the promise of more treatment options in the form of vaccines.

In a 28-person study, researchers focused on interferon alpha, a protein that can determine the severity of lupus. They administered four doses of a vaccine against the protein (manufactured by Neovacs), which caused an antibody response. "This is an early, first step. It appears to be safe. And, the fact that they could show that they could inhibit or down-regulate the interferon signature is very promising," said Dr. Cynthia Aranow, from the Feinstein Institute for Medical Research in Manhasset, NY, according to USA Today.

The other study looked at patients with mild to no lupus activity who were injected with vitamin D for four weeks, followed by monthly doses for 6 months. According to the researchers, the results were promising; none of the 24 patients developed kidney stones or high calcium levels in their bloodstreams, and the treatment boosted their positive immune responses. The treatment also lowered the responses from cells that may play a part in lupus activity.

"It's exciting to see that they were able to reverse some of the immunologic dysfunction associated with lupus, but we need a large randomized clinical trial to confirm this," Aranow said, according to USA Today.

Still, there's much more work to be done. Neither study could determine if the treatments had a clinical response. And the costs of commercially expanding the treatments could be prohibitive.

- check out the USA Today piece

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about lupus   Vitamin D